172 related articles for article (PubMed ID: 38878155)
1. Oxidative stress and its role in Fabry disease.
Cacciapuoti M; Bertoldi G; Caputo I; Driussi G; Carraro G; Calò LA
J Nephrol; 2024 Jun; ():. PubMed ID: 38878155
[TBL] [Abstract][Full Text] [Related]
2. Biochemical Mechanisms beyond Glycosphingolipid Accumulation in Fabry Disease: Might They Provide Additional Therapeutic Treatments?
Bertoldi G; Caputo I; Driussi G; Stefanelli LF; Di Vico V; Carraro G; Nalesso F; Calò LA
J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902850
[TBL] [Abstract][Full Text] [Related]
3. Oxidative Stress and Cardiovascular-Renal Damage in Fabry Disease: Is There Room for a Pathophysiological Involvement?
Ravarotto V; Simioni F; Carraro G; Bertoldi G; Pagnin E; Calò LA
J Clin Med; 2018 Nov; 7(11):. PubMed ID: 30400144
[TBL] [Abstract][Full Text] [Related]
4. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
5. Could nutritional therapy take us further in our approaches to Fabry disease?
Francini-Pesenti F; Ravarotto V; Bertoldi G; Spinella P; Calò LA
Nutrition; 2020 Apr; 72():110664. PubMed ID: 31972420
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Fabry Nephropathy: A Literature Review.
Shimohata H; Yamashita M; Yamada K; Hirayama K; Kobayashi M
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629768
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease.
Germain DP
Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.
Fervenza FC; Torra R; Warnock DG
Biologics; 2008 Dec; 2(4):823-43. PubMed ID: 19707461
[TBL] [Abstract][Full Text] [Related]
10. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
Waldek S; Feriozzi S
BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress biomarkers in Fabry disease: is there a room for them?
Simoncini C; Torri S; Montano V; Chico L; Gruosso F; Tuttolomondo A; Pinto A; Simonetta I; Cianci V; Salviati A; Vicenzi V; Marchi G; Girelli D; Concolino D; Sestito S; Zedde M; Siciliano G; Mancuso M
J Neurol; 2020 Dec; 267(12):3741-3752. PubMed ID: 32719972
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
[TBL] [Abstract][Full Text] [Related]
13. Renal involvement in paediatric Fabry disease.
Sestito S; Falvo F; Sallemi A; Petrisano M; Scuderi MG; Tarsitano F; D'Angelo G; Betta P; Roppa K; Parisi F; Pensabene L; Fede C; Chimenz R; Concolino D
J Biol Regul Homeost Agents; 2019; 33(5 Suppl. 1):59-63. Special Issue: Focus on Pediatric Nephrology. PubMed ID: 31630715
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis.
Muto R; Suzuki Y; Shimizu H; Yasuda K; Ishimoto T; Maruyama S; Ito Y; Mizuno M
Intern Med; 2023 Feb; 62(4):565-569. PubMed ID: 35831104
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy in Fabry disease: clinical implications.
Breunig F; Knoll A; Wanner C
Curr Opin Nephrol Hypertens; 2003 Sep; 12(5):491-5. PubMed ID: 12920395
[TBL] [Abstract][Full Text] [Related]
17. [Fabry disease - the profile of an orphan disease].
Tamò R; Zweifel SA; Beuschlein F; Nowak A
Ther Umsch; 2018 Nov; 75(4):217-224. PubMed ID: 30468120
[TBL] [Abstract][Full Text] [Related]
18. Paediatric Fabry disease.
Ellaway C
Transl Pediatr; 2016 Jan; 5(1):37-42. PubMed ID: 26835405
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?
Ravarotto V; Carraro G; Pagnin E; Bertoldi G; Simioni F; Maiolino G; Martinato M; Landini L; Davis PA; Calò LA
PLoS One; 2018; 13(9):e0204618. PubMed ID: 30261035
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
